Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
HPB (Oxford). 2011 Sep;13(9):605-11. doi: 10.1111/j.1477-2574.2011.00335.x. Epub 2011 Jul 26.
Criteria for selecting patients to receive adjuvant chemotherapy in cases of resected intrahepatic or hilar cholangiocarcinoma (CC) are lacking. Some clinicians advocate the provision of adjuvant therapy in patients with lymph node (LN)-positive disease; however, nodal assessment is often inadequate. The aim of this study was to identify a surrogate criterion based on primary tumour characteristics.
All patients who underwent resection for hilar or intrahepatic CC at a single institution between January 2000 and September 2009 were identified from a prospectively maintained database. Pathological factors were recorded. The primary outcome assessed was overall survival (OS).
In total, 69 patients underwent resection for hilar (n=34) or intrahepatic (n=35) CC. Their median age was 66 years and 27 patients (39%) were male. Median follow-up was 22 months and median OS was 17 months. Median tumour size was 5 cm. Overall, 23% of patients had a positive resection margin, 44% had perineural invasion, 32% had lymphovascular invasion (LVI) and 25% had positive LNs. The median number of LNs removed was two and the median number of positive LNs was zero. The presence of LVI was associated with reduced OS (11.9 months vs. 23.1 months; P=0.023). After accounting for all other adverse tumour factors, the presence of LVI persisted as the only negative prognostic factor for OS on multivariate Cox regression.
In patients who had undergone resection of hilar or intrahepatic CC, the presence of LVI was strongly associated with reduced OS. Thus the finding of LVI may potentially be used as a criterion in the selection of patients for adjuvant chemotherapy.
在切除的肝内或肝门部胆管癌(CC)患者中,缺乏选择接受辅助化疗的标准。一些临床医生主张对淋巴结(LN)阳性疾病的患者提供辅助治疗;然而,淋巴结评估往往不足。本研究旨在根据肿瘤特征确定替代标准。
从 2000 年 1 月至 2009 年 9 月期间在一家机构接受肝门部或肝内 CC 切除术的所有患者均从一个前瞻性维护的数据库中确定。记录病理因素。主要评估的结果是总生存(OS)。
共 69 例患者接受了肝门部(n=34)或肝内(n=35)CC 的切除术。他们的中位年龄为 66 岁,27 例(39%)为男性。中位随访时间为 22 个月,中位 OS 为 17 个月。中位肿瘤大小为 5cm。总的来说,23%的患者有阳性切缘,44%的患者有神经周围侵犯,32%的患者有血管淋巴管侵犯(LVI),25%的患者有阳性 LNs。中位数取出的 LNs 数为 2 个,阳性 LNs 数中位数为 0 个。LVI 的存在与 OS 降低相关(11.9 个月比 23.1 个月;P=0.023)。在考虑所有其他不良肿瘤因素后,LVI 的存在在多变量 Cox 回归中仍然是 OS 的唯一负预后因素。
在接受肝门部或肝内 CC 切除术的患者中,LVI 的存在与 OS 降低密切相关。因此,LVI 的发现可能可作为选择辅助化疗患者的标准。